tiprankstipranks
Advertisement
Advertisement

MBX Biosciences sees cash runway into mid-2027

As of March 31, 2025, MBX Biosciences (MBX) had cash, cash equivalents and marketable securities of $240.8 million. Based on its current operating plan, management expects the combined cash, cash equivalents and marketable securities balance to fund operations into mid-2027.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1